Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04615403 · ClinicalTrials.gov registry record · Phase 2

Study of Exchange of Travoprost Intraocular Implant

A Phase 2 study, sponsored by Glaukos Corporation.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target

NCT04615403 is a Phase 2 study that has completed, run by Glaukos Corporation. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04615403, a Phase 2 study, has completed, sponsored by Glaukos Corporation.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target

Study Summary

The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG Travoprost

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2020-11-19
Est. Completion 2022-02-28
Phase Phase 2

Sponsor

Glaukos Corporation

33 total trials

What the Registry Record Tells You About NCT04615403

The ClinicalTrials.gov registry entry for NCT04615403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Travoprost is the first listed.

NCT04615403 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04615403 about?

NCT04615403 is a clinical study titled "Study of Exchange of Travoprost Intraocular Implant". The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT04615403?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2020-11-19. Estimated completion is 2022-02-28.

What interventions are being tested in trial NCT04615403?

The interventions under investigation include: Travoprost (DRUG).

Who is sponsoring clinical trial NCT04615403?

This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.